← Back to patent-cliff list
CAS 123-30-8
4-aminophenol4-Hydroxyaniline
Codes: CABO-011, Ceftazidime-035, SORF-004
Application context (from source-drug indications)
Neuroendocrine tumourCabozantinib S-malatePancreatic neuroendocrine tumourCabozantinib S-malateRenal cell carcinomaCabozantinib S-malateHepatocellular carcinomaCabozantinib S-malateThyroid cancerCabozantinib S-malateNeuroendocrine carcinomaCabozantinib S-malateCystitisAvibactam Sodium/CeftazidimeCholecystitisAvibactam Sodium/CeftazidimePeritonitisAvibactam Sodium/CeftazidimeIntra-abdominal infectionAvibactam Sodium/CeftazidimeLiver abscessAvibactam Sodium/CeftazidimeSepsisAvibactam Sodium/CeftazidimeBacterial infectionCeftazidime/Tazobactam SodiumRespiratory tract infectionCeftazidime/Tazobactam SodiumUrinary tract infectionCeftazidime/Tazobactam SodiumThyroid cancerSorafenib TosylateHepatocellular carcinomaSorafenib TosylateRenal cell carcinomaSorafenib TosylateAggressive fibromatosisSorafenib TosylateLiver cancerSorafenib TosylateMyeloproliferative neoplasmSorafenib TosylateBacterial infectionCeftazidimeGram-positive bacterial infectionCeftazidimeGram-negative bacterial infectionCeftazidimeGynaecological disorderCeftazidimeIntra-abdominal infectionCeftazidimeOsteoarthritisCeftazidime
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Cabozantinib S-malate | Tier B — Position early | 2029 |
| Avibactam Sodium/Ceftazidime | Tier C — Watch / trade | - |
| Ceftazidime/Tazobactam Sodium | Tier C — Watch / trade | - |
| Sorafenib Tosylate | Tier B — Position early | - |
| Ceftazidime | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-(3,4-dimethoxyphenyl)ethan-1-one→1-(4,5-dimethoxy-2-nitrophenyl)ethanone→1-(2-amino-4,5-dimethoxyphenyl)ethanone→ethyl formate→6,7-dimethoxyquinolin-4-ol→6,7-dimethoxyquinolin-4-yl trifluoromethanesulfonate→N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide→cyclopropane-1,1-dicarboxylic acid→4-fluoroaniline→methyl 1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylate→4-aminophenol
4-fluoroaniline→4-aminophenol→4-chloro-6,7-dimethoxyquinoline→diethyl cyclopropane-1,1-dicarboxylate→1-(ethoxycarbonyl)cyclopropane-1-carboxylic acid→ethyl 1-((4-hydroxyphenyl)carbamoyl)cyclopropane-1-carboxylate→ethyl 1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate→1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylic acid
4-(Dimethylamino)phenol→tert-Butyl (5Z)-5-(2-amino-1,3-thiazol-4-yl)-8,8-dimethyl-4-oxo-3,7-dioxa-2-thia-6-azanon-5-en-9-oate 2,2-dioxide→4-Methoxybenzyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate→1-[[(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-2-[[(4-methoxybenzyl)oxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium chloride→4-Hydroxyaniline→(2Z)-(2-Amino-1,3-thiazol-4-yl)[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetic acid→Pyridine→4-Methoxybenzyl (6R,7R)-7-amino-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride
4-(Dimethylamino)phenol→tert-Butyl (5Z)-5-(2-amino-1,3-thiazol-4-yl)-8,8-dimethyl-4-oxo-3,7-dioxa-2-thia-6-azanon-5-en-9-oate 2,2-dioxide→4-Methoxybenzyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate→1-[[(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-2-[[(4-methoxybenzyl)oxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium chloride→4-Hydroxyaniline→(2Z)-(2-Amino-1,3-thiazol-4-yl)[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetic acid→Pyridine→4-Methoxybenzyl (6R,7R)-7-amino-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride
4-(Dimethylamino)phenol→tert-Butyl (5Z)-5-(2-amino-1,3-thiazol-4-yl)-8,8-dimethyl-4-oxo-3,7-dioxa-2-thia-6-azanon-5-en-9-oate 2,2-dioxide→4-Methoxybenzyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate→1-[[(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetyl]amino]-2-[[(4-methoxybenzyl)oxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium chloride→4-Hydroxyaniline→(2Z)-(2-Amino-1,3-thiazol-4-yl)[[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino]acetic acid→Pyridine→4-Methoxybenzyl (6R,7R)-7-amino-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Hydroxy-6,7-dimethoxyqunioline Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-((6,7-Dimethoxyquinolin -4-yl)oxy)aniline Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.